Jeffrey Bradley named interim chair of Emory Department of Radiation Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeffrey Bradley was named interim chairman of the Emory University Department of Radiation Oncology.

Bradley, previously the executive vice chairman of the department, succeeds former Winship Cancer Institute Executive Director Walter J. Curran, Jr., who announced in October 2020 that he would be stepping down from his role as chair (The Cancer Letter, Jan 22, 2021).

Bradley joined Winship in 2019 from Washington University School of Medicine in St. Louis where he was the S. Lee Kling Endowed Professor of Radiation Oncology and clinical director of the Kling Proton Center.

Bradley led the effort to open the world’s first single-room proton center at Washington University’s Barnes-Jewish Hospital. He is a founding member of the Particle Therapy Oncology Group of North America and the chairman of the NRG Oncology Lung Cancer Committee.

Since joining Winship, Bradley has been appointed the James W. Keller, MD Distinguished Professorship in Radiation Oncology in support of his research in innovative radiation therapy technologies such as proton beam therapy and stereotactic body radiation therapy.

Curran was chairman of the Department of Radiation Oncology for 13 years. He led efforts to open the Emory Proton Therapy Center, exclusively operated by department faculty and staff, which treated over 400 patients in its first year, and expanded basic, translational, and clinical research during his tenure.

In mid-January, the Department of Radiation Oncology appointed Curran as professor emeritus.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login